Estradiol is used to treat symptoms of menopause like hot flashes and vaginal dryness, and to prevent bone loss in postmenopausal women. It's also used as hormone replacement therapy and to treat certain hormone-related cancers and conditions.[2] Estrace is currently approved and in use across 62 indications[4].[1]
Estrace is one of 1287 small molecule programs targeting Insulin resistance. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
2828 competitors in Breast Cancer
Estrace
Halaven
DATROWAY
MS Contin
Lexiscan
Adenocard
Zolymbus
Effexor
Sporanox
Chantix
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
DELESTROGEN
NDA NDA009402
Sep 10, 1986
ESTRADERM
NDA NDA019081
Apr 26, 1996
ESTRING
NDA NDA020472
Dec 3, 1996
FEMPATCH
NDA NDA020417
Aug 4, 1998
ESCLIM
NDA NDA020847
Mar 5, 1999
CLIMARA
NDA NDA020375
Sep 20, 1999
ESTRADIOL
NDA NDA021048
Aug 16, 2000
VIVELLE
NDA NDA020323
Apr 5, 2002
ALORA
NDA NDA020655
May 3, 2002
VIVELLE-DOT
NDA NDA020538
Mar 20, 2003
FEMRING
NDA NDA021367
Oct 9, 2003
ESTRASORB
NDA NDA021371
Feb 9, 2004
ESTROGEL
NDA NDA021166
Jun 8, 2004
MENOSTAR
NDA NDA021674
Aug 20, 2004
FEMTRACE
NDA NDA021633
Dec 15, 2006
ELESTRIN
NDA NDA021813
Jun 4, 2007
DIVIGEL
NDA NDA022038
Jul 27, 2007
EVAMIST
NDA NDA022014
Nov 25, 2009
VAGIFEM
NDA NDA020908
Sep 23, 2014
MINIVELLE
NDA NDA203752
May 29, 2018
IMVEXXY
NDA NDA208564
Sources
Details
Patent Cliff
Jul 10, 2028
Earliest patent expiration — generic entry possible after this date